ANKRD24 Inhibitors
ANKRD24 inhibitors represent a distinctive category of compounds designed to selectively target epigenetic regulators, thereby exerting control over the expression of ANKRD24. Among these inhibitors, A-485 stands out as a p300/CBP inhibitor that indirectly impacts ANKRD24 by inducing alterations in histone acetylation patterns. Similarly, GSK-J4 and C646, acting as inhibitors of JMJD3 and p300/CBP, respectively, influence ANKRD24 through their ability to modulate epigenetic modifications. EPZ-6438, also known as Tazemetostat, and JQ1 belong to this group, targeting EZH2 and BET bromodomains, respectively, and exerting their influence on ANKRD24 by modifying chromatin states. Additionally, SAHA, UNC1999, GSK343, BRD4770, PFI-1, UNC3866, and CPI-169, which are designed to target HDACs, G9a/GLP, EZH2, and BET bromodomains, indirectly modulate ANKRD24 by epigenetically regulating its transcriptional control.
This diverse array of inhibitors serves as invaluable tools in dissecting the intricate landscape of epigenetic regulation surrounding ANKRD24 and aids in comprehending its nuanced role in various cellular processes. The targeted modulation of ANKRD24 through these inhibitors not only sheds light on the intricacies of its regulatory network but also opens avenues for interventions. Researchers can leverage these chemical tools to meticulously investigate the epigenetic cues governing ANKRD24 expression and function, thereby advancing our understanding of the molecular mechanisms underlying its involvement in cellular pathways. In summary, the unique properties of ANKRD24 inhibitors, exemplified by A-485, GSK-J4, C646, EPZ-6438, JQ1, SAHA, UNC1999, GSK343, BRD4770, PFI-1, UNC3866, and CPI-169, offer a rich and diverse toolkit for researchers delving into the intricate world of epigenetic regulation and ANKRD24's role in cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-485 | 1889279-16-6 | sc-507493 | 5 mg | $275.00 | ||
A-485 is a selective inhibitor of p300 and CBP histone acetyltransferases. By targeting these enzymes, A-485 modulates histone acetylation, affecting the chromatin landscape. This epigenetic modulation can indirectly influence ANKRD24 expression and activity by altering the accessibility of the genomic regions involved in ANKRD24 regulation. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4 is a specific inhibitor of the histone demethylase JMJD3. By inhibiting JMJD3, GSK-J4 leads to the accumulation of H3K27me3, influencing gene expression patterns. This epigenetic alteration can indirectly impact ANKRD24 by affecting the chromatin state of regulatory regions, potentially modulating its transcription and subsequent cellular functions. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646 is a potent and selective inhibitor of the histone acetyltransferase p300/CBP. By blocking p300/CBP activity, C646 disrupts histone acetylation dynamics, affecting gene expression. This epigenetic modulation can indirectly influence ANKRD24 by altering the chromatin environment and accessibility of genomic regions involved in ANKRD24 regulation. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
EPZ-6438 is a selective inhibitor of the histone methyltransferase EZH2. By targeting EZH2, EPZ-6438 modulates H3K27 methylation, influencing gene expression. This epigenetic regulation can indirectly impact ANKRD24 by altering the chromatin state of genomic regions involved in ANKRD24 transcriptional control. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a selective BET bromodomain inhibitor that disrupts interactions between bromodomains and acetylated histones. By inhibiting BET proteins, JQ1 affects chromatin accessibility and gene expression. This epigenetic modulation can indirectly influence ANKRD24 by altering the chromatin landscape and accessibility of regulatory regions controlling ANKRD24 expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
SAHA is a histone deacetylase (HDAC) inhibitor that globally alters histone acetylation. By inhibiting HDACs, SAHA influences gene expression patterns. This epigenetic modulation can indirectly impact ANKRD24 by altering the acetylation status of histones in regulatory regions, potentially influencing the transcriptional control of ANKRD24. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999 is a selective inhibitor of the histone methyltransferase G9a/GLP. By targeting G9a/GLP, UNC1999 modulates H3K9 methylation, influencing gene expression. This epigenetic regulation can indirectly impact ANKRD24 by altering the chromatin state of genomic regions involved in ANKRD24 transcriptional control. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $151.00 $461.00 | 1 | |
GSK343 is a potent and selective inhibitor of the histone lysine methyltransferase EZH2. By targeting EZH2, GSK343 modulates H3K27 methylation, affecting gene expression. This epigenetic modulation can indirectly influence ANKRD24 by altering the chromatin state of genomic regions involved in ANKRD24 transcriptional control. | ||||||
PFI-1 | 1403764-72-6 | sc-478504 | 5 mg | $98.00 | ||
PFI-1 is a selective inhibitor of BET bromodomains, disrupting their interactions with acetylated histones. By inhibiting BET proteins, PFI-1 affects chromatin accessibility and gene expression. This epigenetic modulation can indirectly influence ANKRD24 by altering the chromatin landscape and accessibility of regulatory regions controlling ANKRD24 expression. | ||||||